Social dysfunction

Social dysfunction characterises a number of socially deficit mental disorders that affects social functioning.[1][2] Social dysfunction is a core symptom of social anxiety disorder (social phobia), autism, dementia, PTSD, schizophrenia and some personality disorders.[1][2][3]

Oxytocin receptor agonists, like oxytocin and LIT-001, and CA7 are of theoretical interest in the potential medical treatment of social dysfunction.[2][4][3]

References

  1. ^ a b Hrdlicka M, Dudova I (March 2013). "Controversies in autism: is a broader model of social disorders needed?". Child Adolesc Psychiatry Ment Health. 7 (1): 9. doi:10.1186/1753-2000-7-9. PMC 3606474. PMID 23506384.
  2. ^ a b c Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M (August 2011). "Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine". Nat Rev Neurosci. 12 (9): 524–38. doi:10.1038/nrn3044. PMID 21852800.
  3. ^ a b Spotlight Showcases: Kinoxis Therapeutics Pty Ltd. 5th Annual Neruoscience Innovation Forum for Business Development, Licensing & Investment 22nd–23rd March 2022, Digital Conference. March 2022. Kinoxis' second series of compounds target the oxytocin receptor, through either selective partial agonism or positive allosteric modulation. The brain oxytocin system has been identified as perhaps the most important molecular target for regulating social behaviour and is therefore a major target of interest for treating a wide range of mental disorders. The development of these compounds will be focused on treating conditions that feature social dysfunction as a core symptom, such as neurodevelopmental disorders (including autism spectrum disorder), social anxiety disorder, dementia (including Alzheimer's disease), PTSD and schizophrenia. The KNX200 series of oxytocin receptor partial agonists are undergoing candidate selection stage using several pre-clinical animal disease models (Alzheimer's, PTSD, ASD) and the KNX300/400 series of oxytocin receptor positive allosteric modulators are undergoing lead optimisation.
  4. ^ Hilfiger L, Zhao Q, Kerspern D, Inquimbert P, Andry V, Goumon Y, Darbon P, Hibert M, Charlet A (February 2020). "A Nonpeptide Oxytocin Receptor Agonist for a Durable Relief of Inflammatory Pain". Sci Rep. 10 (1): 3017. doi:10.1038/s41598-020-59929-w. PMC 7033278. PMID 32080303.



Stub icon

This article about a mental disorder and related topics is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.